Boston Immune Technologies & Therapeutics

At Swedish biotech BioInvent , early-stage data on two anti-tumor necrosis factor receptor 2 (TNFR2) antibodies are starting to show promise. Presenting at the annual Society for Immunotherapy for Ca

Biopharmaceutical companies raised $1.5bn in 11 venture capital mega-rounds of $100m or more during the last week and a half of March. Including VC and other financings under $100m, 35 privately held

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Emmaus, Kainos Tie Up To Develop IRAK4